Long­time biotech leader Pearl Huang takes the reins as CEO of No­var­tis-backed up­start

It has on­ly been a few months since Pearl Huang ex­it­ed the top seat at Cyg­nal Ther­a­peu­tics, but now she’s back at the helm of an­oth­er biotech.

Af­ter tak­ing a few months off — pass­ing an ex­am in that time to get her cap­tain’s li­cense from the US Coast Guard — she’s been named CEO of Dunad Ther­a­peu­tics, a biotech fo­cused on de­vel­op­ing a small mol­e­cule co­va­lent ther­a­pies that was found­ed in 2020. Huang told End­points News that two fac­tors at­tract­ed her to go­ing back to the c-suite: the com­pa­ny’s tech­nol­o­gy and its co-founders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER